Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Humacyte (NASDAQ:HUMA) and maintained a $7 price target.
July 02, 2024 | 2:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Humacyte and maintained a $7 price target.
The reiteration of an Overweight rating and the maintenance of a $7 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100